Gene Therapy For Lethal Glycogen Storage Disease Wins EMA PRIME Designation
Ten products have been granted PRIME designation so far this year
Executive Summary
Investigational products from Ultragenyx and MinervaX secured a place on the European Medicines Agency’s priority medicines scheme this month.